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Ethnopharmacological relevance: The endemic succulent South African plant, Sceletium tortuosum (L.) N.E.
Br. (synonym Mesembryanthemum tortuosum L.), of the family Mesembryathemaceae, has an ancient oral
tradition history of use by San and Khoikhoi people as an integral part of the indigenous culture and
materia medica. A special standardized extract of Sceletium tortuosum (Zembrins) has been developed
and tested pre-clinically in rats, and clinically in healthy subjects.
Aim of the study: The present investigation aimed at the construction of electropharmacograms of
Zembrins in the presence of three dosages (2.5, 5.0 and 10.0 mg/kg), and comparative electro-
pharmacograms and discriminatory analyses for other herbal extracts, citicoline and rolipram.
Material and methods: Seventeen adult Fischer rats were each implanted with a set consisting of four
bipolar concentric steel electrodes ﬁxed by dental cement and three screws driven into the scalp. After
two weeks of recovery from surgery the animals were adapted to oral administration by gavage and to
experimental conditions (45 min pre-drug period and 5 h of recording after a rest of 5 min for calming
down). Data were transmitted wirelessly and processed using a Fast Fourier Transformation (FFT).
Spectral power was evaluated for 8 frequency ranges, namely delta, theta, alpha1, alpha2, beta1a, beta1b,
beta2 and gamma power.
Results: Zembrins dose dependently attenuated all frequency ranges, to varying degrees. The most
prominent was the statistically signiﬁcant reduction in alpha2 and beta1a waves, correlated with acti-
vation of the dopaminergic and glutamatergic transmitter systems respectively. This feature is common
to all synthetic and herbal stimulants tested to date. The second strongest effects were reduction in both
the delta and the theta frequency ranges, correlated with changes in the cholinergic and norepinephrine
systems respectively, a pattern seen in preparations prescribed for neurodegenerative diseases. Theta
wave reduction in common with the delta, alpha2 and beta1 attenuation has been noted for analgesic
drugs. Attenuation of alpha1 waves emerged during the highest dosage in all brain areas, a feature seen
in all antidepressants.
Discussion: The electropharmacogram of Zembrins was compared to the electropharmacograms of
herbal extracts archived in our database. Extracts of Oenothera biennis and Cimicifuga racemosa gave a
very similar electropharmacograms to that of Zembrins, and extracts of Ginkgo biloba and Rhodiola rosea
gave rather similar electropharmacograms to Zembrins. Linear discriminant analysis conﬁrmed these
similarities and demonstrated that all three dosages of Zembrins plotted in close neighbourhood to each
other. Citocoline, a synthetic compound originally developed for cognitive enhancement, had a similar
electropharmacogram to Zembrins. Similarity to the electropharmacograms of the synthetic phospho-
diesterase-4 inhibitor, rolipram, suggests Zembrins has antidepressant and cognitive function enhancing
potential.
Conclusion: The combined results from the electropharmacograms and comparative discriminatory
analyses suggest that Zembrins has dose dependent activity, with potential applications as a cognitive
function enhancer, as an antidepressant, and as an analgesic.
& 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).r Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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web.co.za (N. Gericke).
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1.1. Ethnobotanical background
The endemic succulent South African plant, Sceletium tortuo-
sum (L.) N.E. Br. (synonym Mesembryanthemum tortuosum L.), of
the family Mesembryathemaceae, has an ancient oral tradition
history of use by San and Khoikhoi people as an integral part of the
indigenous culture and materia medica. The use of the plant by
indigenous people was ﬁrst documented by the ﬁrst Governor of
the Cape Colony, Simon van der Stel in 1685, this report was ac-
companied by a remarkably detailed painting of the plant (Wa-
terhouse et al., 1979).
Sceletium tortuosum has been traditionally used by hunter-
gatherers and pastoralists for endurance on hunting forays, and for
coping with the stress of living in the challenging arid environ-
ments of Bushmanland, Namaqualand and the Karoo. The in-
digenous Nama name for Sceletium tortuosum is Kanna, or Channa,
while the name given to the plant by the /Xam San people was!
Kwain. The Dutch colonists called Sceletium tortuosum Kaauwgoed
or Kauwgood (Pappe, 1868; Smith, 1966) which translates as
“chewing stuff’.
Dried Sceletium plant material was once widely traded in
South Africa among indigenous people and in more recent his-
torical times it was sold through rural trading stores. An intriguing
ethnobotanical record from 1873 alludes to a memory-enhancing
activity for Sceletium. Manuscript MSS BC151 006 from the
Manuscript and Archives Department of the University of Cape
Town documents the information on Kaauwgoed related by the
/Xam San informant /Kabbo to the German linguist Wilhelm Bleek:
“It is chewed by Bushmen, and gives strength to their limbs; and takes
away pain, and make[s] their memory strong”.
Over the last two decades increasing numbers of botanical
supplements, health teas and beverages containing Sceletium tor-
tuosum have become available through farm stalls, health food
shops, pharmacies and via internet sales. The products are typi-
cally used for promoting a sense of calm and wellbeing, relieving
stress, elevating mood and reducing anxiety (Gericke and Viljoen,
2008), and by students to enhance concentration during exam
times.
During ethnobotanical documentation of Sceletium tortuosum
in 1995, elderly folk from the Namaqualand hamlets of Paulshoek
and Nourivier were interviewed who had chewed Sceletium daily
for the past thirty to forty years of their lives (Gericke and Viljoen,
2008). One of us (NG) noted that these elderly people were in
surprisingly good general health and seemed more lucid than was
typical their age-peers from other rural areas in South Africa
where Sceletium is not available, and speculated that long-term
Sceletium use may have neuro-protective properties.
Veterinarian studies in Japan demonstrated that Sceletium tor-
tuosum reduced cage stress and travel stress in companion animal
cats, and decreased the excessive crying and nocturnal barking of
aged cats and dogs with a clinical diagnosis of dementia (Hir-
abayashi et al., 2002, 2004, 2005), while the ﬁrst clinical case-re-
ports on Sceletium tortuosum described rapid onset of anxiolytic
and antidepressant activity, and mentioned anecdotal reports on
the use of Sceletium in South Africa for the management of drug
addiction at a community treatment centre (Gericke, 2001).
A proprietary standardized and characterized extract of culti-
vated Sceletium tortuosum (Zembrins), a dual 5-HT uptake in-
hibitor and PDE4 inhibitor (Harvey et al., 2011), was shown to be
safe and well tolerated in pre-clinical and clinical studies (Mur-
bach et al., 2014; Nell et al., 2013). The acute effects of Extract
Sceletium tortuosum (Zembrins) administration in 16 healthy
young adults was studied in a pharmaco-fMRI study focused on
anxiety-related activity in the amygdala and its connected neuro-circuitry. Amygdala reactivity to fearful faces under low perceptual
load conditions was attenuated after a single 25.0 mg dose of
Zembrins. Follow-up connectivity analysis on the emotion
matching task demonstrated that amygdala–hypothalamus cou-
pling was also reduced. These results demonstrated for the ﬁrst
time the attenuating effects of Sceletium tortuosum on the threat
circuitry of the human brain and provide supporting evidence that
the dual 5-HT reuptake inhibition and PDE4 inhibition of Zem-
brins might have anxiolytic potential by attenuating the sub-
cortical threat response (Terburg et al., 2013).
The neurocognitive effects of extract Sceletium tortuosum
(Zembrins) was tested for the ﬁrst time in a group of adults
(n¼21, mean age 54.6 years) using the CNS Vital Signss battery of
tests. Zembrins at 25.0 mg daily dosage signiﬁcantly improved
executive function and cognitive set ﬂexibility compared with the
placebo group. It was concluded that the promising cognitive en-
hancing effects of Zembrin
s
supported PDE-4 inhibition as a me-
chanism of action, and PDE4-cAMP-PCREB cascade, suggesting
potential application in managing early Alzheimer’s Disease (Chiu
et al., 2014).
1.2. Neurophysiological background
Drugs exert their action within the organism by interaction
with targets deﬁned biochemically (receptors, enzymes, channels
transporters et cetera), large protein molecules sometimes also
sitting at the outer surface of cells. With respect to the central
nervous system neurotransmitter receptors represent main targets
of drugs. Interaction of drugs with these molecules induces a
signalling cascade, which ﬁnally ends up with the control of ion
channel conductance. Since the electric activity of single neurons
depends on the set of momentarily active ion channels, commu-
nication between neurons is governed by channel activity. From
here, it is obvious that ﬁeld potentials contain the information of
larger local networks of electrically active neurons, by it reﬂecting
the interaction of drugs with their targets within the concert of
neurotransmission.
Frequency analysis of the ﬁeld potentials in the presence of
drugs can be depicted as the so-called electropharmacogram,
which has been widely used to characterize drug actions on rat
(Christian et al., 2015) and human brains (Alonso et al., 2015).
Interpretation of the results is made with respect to the likely
underlying neurotransmitter activity responsible for changes in
the selected frequency ranges, and aims at advancing an under-
standing of possible clinical applications in humans. The re-
lationship between EEG delta waves and cholinergic neuro-
transmission was ﬁrst recognised in 2005 (Dimpfel, 2005), while it
was recognized that theta waves are inﬂuenced by drugs acting at
the biochemically deﬁned norepinephrine alpha2 receptor
(Dimpfel and Schober, 2001). Presynaptic interaction with this
receptor leads to drowsiness and sleep, and increases of theta
waves have been used as part of a formula describing depth of
sleep in humans. Dopaminergic activity is reﬂected by changes in
alpha2 frequencies (Dimpfel, 2008).
1.3. Aim of the present study
The convergence of prior evidence (ethnobotanical, in-vitro
mechanism of action, companion animal studies, and clinical re-
search) suggests that Zembrins has cognitive-enhancing potential,
and the present study was undertaken as part of a translational
research initiative to characterize the effect of Zembrins in a rat
pharmaco-EEG (local ﬁeld potentials). It was anticipated that ad-
ditional insights into Zembrin'ss activity on the brain could be
obtained from changes over time in the local ﬁeld potential (LFP)
of deﬁned frequency ranges, recorded from four areas of the rat
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be compared with a databased reference collection of botanicals
and supplements, as well as to the pharmacogram of the arche-
typal research phosphodiesterase-4 inhibitor (PDE4 inhibitor),
rolipram.2. Material and methods
2.1. Local ﬁeld potentials (LFP)
Local ﬁeld potentials were recorded from frontal cortex, hip-
pocampus, striatum and reticular formation of freely moving rats
from inside a totally copper shielded room. Signals were wirelessly
transmitted by a radio-telemetric system (Rhema Labortechnik,
Hofheim, Germany, using 40 MHz as carrier frequency) and were
ampliﬁed and processed as described earlier to give power spectra
with 0.25 Hz resolution (Dimpfel et al., 1986). In short, after au-
tomatic artefact rejection signals were collected in sweeps of 4 s
duration and Fast Fourier transformed using a Hanning window.
Sampling frequency was 512 Hz. Four values were averaged to give
a ﬁnal sampling frequency of 128 Hz, well above the Nyquist fre-
quency. The resulting electrical power spectra were divided into
6 specially deﬁned frequency ranges (delta: 1.50–4.00 Hz; theta:
4.25–6.75 Hz; alpha1: 7.00–9.50 Hz; alpha2: 9.75–12.25 Hz; be-
ta1a: 12.50–15.00 Hz; beta1b: 15.25–17.75 Hz; beta2: 18.00–
34.25 Hz; gamma: 34.50–81.00 Hz). Spectra were averaged in
steps of 3 min each and displayed on-line. In an off-line procedure
spectra were averaged to give longer periods for further analysis
and data presentation.
2.2. Test Item
All dosages of the compound Zembrins (2.5 mg/kg, 5.0 mg/kg
and 10.0 mg/kg) were tested by oral administration by gavage. The
“Tele-Stereo-EEG” animal model consisting of continuous record-
ing of intracerebral ﬁeld potentials was used in combination with a
video tracking system for detection of changes in motility (GJB
Datentechnik GmbH, D-98704 Langewiesen, Germany). This sys-
tem recognized locomotion as well as stereotyped behaviour by
following a contrast difference of the black transmitter on the
head of the animal in comparison to its environment. The system
has been validated in a previous study with different dosages of
caffeine.
Solutions were prepared fresh for each experimental day and
administered orally by gavage after 45 min of pre-drug Vehicle
recording. Vehicle was 0.9% NaCl. Zembrins (Batch 110325) from
HG&H Pharmaceuticals (Pty) Ltd, South Africa was tested in three
dosages (2.5, 5.0 and 10.0 mg/kg).
2.3. Animals and management
Eighteen adult Fisher 344 rats (11 month of age or 15 month of
age) and day-night converted, weight about 420 g, provided by
Charles River Laboratories, D-97633, Sulzfeld) were used in two
experimental series. Animals were implanted with electrodes into
the brain and were given two weeks for recovery from surgery.
After this, the transmitter was plugged in for adaptation and
control experiments. During the recording rats were not restricted
and could move freely but did not have food available (chewing
would have produced too many artefacts). The principles of la-
boratory animal care were followed in all trials and the local au-
thorities responsible for animal care allowed the performance
according to German Health Guidelines (Code: V54 19c 20 15h 01
NeuroCode Nr. 118/2014 A3/2014 by “Regierungspräsidium” Gies-
sen, Germany). Details of the acclimatisation, housing conditionsand surgery have been reported (Dimpfel, 2013).
2.4. Treatment groups
A crossover design with at least one week of drug holidays in
between the administrations was used. Controls consisted of orally
administration of 1 ml/kg of vehicle for Zembrins 2.5 mg/kg,
5.0 mg/kg and 10.0 mg/kg. After a pre-drug period of 45 min for
pre-drug recording, drug effects were observed continuously on
the screen (artefact control) for 300 min subdivided into 15 min
periods after a lag time of 5 min for calming of animals after orally
administration. Changes of electric power (mV2) are expressed as %
of the 45 min lasting absolute pre-drug spectral power values
within each frequency band. Data were averaged from 16 animals
for each series since there were some missing data in different rats
in each of the series for technical reasons. Data are expressed as
mean values7S.E.M. Statistics were calculated by means of the
Wilcoxon, Mann, Whitney U-test.
2.5. Route and means of administration
Dose levels of Zembrins (2.5 mg/kg, 5.0 mg/kg and 10.0 mg/kg)
were calculated starting from clinical dosage based on the pro-
posal of Shannon et al. (2007). The animals were dosed orally by a
gavage at a constant volume of 1 ml dosing solution per kg of body
weight. The dosage administered to each animal was determined
each day by the weight of that animal at the time of
administration.
2.6. Statistical analysis
Wilcoxon, Mann, Whitney U-test was used throughout all ex-
perimental data for comparison to results obtained by vehicle in-
jection at the particular timing. For comparison of data to re-
ference compounds tested earlier under identical conditions linear
discriminant analysis according to Fischer was used. A total of the
classic 24 variables (six frequency ranges times 4 brain areas) were
used for analysis. Please note, that this analysis does not contain
gamma activity for historical reasons (gamma activity was not
recorded earlier!) Firstly, projection of the results from reference
compounds plus physiological sleep was performed using the
three spatial coordinates for the ﬁrst three discriminant-axes.
Secondly, coding of the result of the fourth to sixth discriminant
analysis into red, green and blue was followed by an additive
colour mixture in analogy to the so-called RGB mode (as used in
TV). A reference matrix of earlier tested drug actions is kept con-
stant (preparations labelled as “Substance Deﬁnition”)) for clas-
siﬁcation of unknown preparations (preparations labelled as
“Substance Analysis”).3. Results
3.1. Effect of vehicle
Orally administration of the vehicle did only result in very
minor changes of spectral power within the four brain areas.
During the third to the ﬁfth hour a tiny increase of delta and al-
pha2 power emerged only in the frontal cortex. A complete time
line is given in Fig. 1.
3.2. Electropharmacogram of Zembrins
Oral administration of the lowest dosage of Zembrins (2.5 mg/
kg) resulted in a highly statistically signiﬁcant attenuation of
spectral power in all frequencies except for gamma within the
Fig. 1. Effect of Vehicle: time dependence of changes of spectral power (Ordinate) in % of the 45 min lasting pre-drug baseline values in four brain regions of the freely
moving rat in the presence of Vehicle (1 ml/kg). Frequency ranges are depicted as coloured bar graphs on the abscissa representing delta (red), theta (orange), alpha1
(yellow), alpha2 (green), beta1a (light blue) and beta1b (dark blue) and gamma spectral power (violet) from left to right within the four brain areas as mentioned on top of
the graph. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Effects of Zembrins (2.5 mg/kg): for other details see legend to Fig. 1. Statistical signiﬁcance in comparison to control (vehicle) is documented by asterisks:
*¼po0.05; **¼po0.01; ***¼po0.001.
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theta, alpha2 and beta1a spectral power was signiﬁcantly atte-
nuated. Within the striatum, only delta and beta power were
signiﬁcantly reduced. In the reticular formation delta, alpha2 and
beta1a power was diminished. Almost identical changes wererecorded during the second hour after administration, however,
statistical signiﬁcance was only reached in recordings from the
frontal cortex. During the third hour, statistically signiﬁcant at-
tenuation of all frequencies was seen in the frontal cortex, an effect
lasting to the 4th hour. A complete time line is given in Fig. 2.
Fig. 3. Effects of Zembrins (5.0 mg/kg): For other details see legend to Fig. 1. Statistical signiﬁcance in comparison to control (vehicle) is documented by asterisks:
*¼po0.05; **¼po0.01; ***¼po0.001.
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resulted in a statistically signiﬁcant attenuation of spectral power
within all frequencies except for gamma in the frontal cortex
during the ﬁrst hour providing a very similar pattern of changes as
observed for the lower dosage. However, changes in the hippo-
campus were less statistically signiﬁcant despite the same pattern
was produced. In general, changes of the frequency pattern wereFig. 4. Effects of Zembrins (10.0 mg/kg): for other details see legend to Fig. 1. Statis
*¼po0.05; **¼po0.01; ***¼po0.001.dominated by attenuation of alpha2 and beta1a frequencies. The
changes were nearly identical during the second hour. But changes
emerged in the gamma range in form of increases, not observed in
the presence of the lowest dosage. But they did not reach statis-
tical signiﬁcance. After this time only a signiﬁcant decrease of al-
pha1 power was seen in the cortex and hippocampus. A complete
time line is given in Fig. 3.tical signiﬁcance in comparison to control (vehicle) is documented by asterisks:
Fig. 5. Dose dependent Effect of Zembrins (5–65 min): For other details see legend to Fig. 1. Statistical signiﬁcance in comparison to control (vehicle) is documented by
asterisks: *¼po0.05; **¼po0.01; ***¼po0.001.
Table 1
Effects of Zembrins on motion. Changes in motion (cm/h) given for the whole time
course of 5 h after drug administration in hourly intervals. Mean average values are
given7S.E.M. Statistical comparison to the results with control (Vehicle) were
determined using the Wilcoxon, Mann, Whitney U-test (p values are given on the
right side).
Motion [cm/h]
Time
[min]
NaCl 0.9%
1 ml/kg
n¼18
Zembrins
2.5 mg/kg
n¼16
Zembrins 5.0 mg/kg
n¼16
Zembrins
10.0 mg/kg
n¼16
45
to 0
788.567107 638.887102 640.04799 640.96776
5–65 838.48777 724.66764 710.29778 779.11780
65–
125
803.597108 823.59772 742.60773 784.527111
125–
185
751.87785 781.96773 654.787107 808.817121
185–
245
769.43779 642.39782 555.93789 0.056 643.73797
245–
305
632.58777 621.637107 574.39781 618.897121
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resulted in a statistically signiﬁcant attenuation of spectral power
within all frequencies except for beta2 and gamma in the frontal
cortex during the ﬁrst hour, providing a very similar pattern of
changes as observed for the lower dosages. Gamma spectral power
was statistically signiﬁcantly increased in the striatum and re-
ticular formation during the ﬁrst hour as a new feature. The other
changes in the striatum and reticular formation were similar so
those observed in the lower dosages. A complete time line is given
in Fig. 4.
The dose dependent effects of Zembrins on the electro-
pharmacogram are shown in Fig. 5, for the 3 doses studied. From
this comparison it becomes obvious that the overall pattern of
changes is stable and reproducible. With respect to alpha1 fre-
quency, attenuation is clearly dose dependent with higher reduc-
tion at higher dosage. With respect to gamma frequency an in-
crease is clearly dose dependent.
3.3. Effect of Zembrins with respect to motion
Motion in the presence of Zembrins did not change except for
the 4th hour in the presence of 5.0 mg/kg. However, comparing
this change to changes in the baseline (saline) value, no real dif-
ference can be assumed. During this time a statistically signiﬁcant
reduction was observed (Table 1). However, there was quite a
scatter of data making it difﬁcult to draw ﬁrm conclusions.4. Discussion
Construction of electropharmacograms has been successfully
used during drug discovery (Dimpfel, 2015). Based on numerous
experimental results it has been concluded that preparations in-
ducing a similar pattern of changes of spectral power have similar
clinical therapeutic indications (Dimpfel, 2003). Zembrins dosedependently induced attenuation of all frequency ranges to a
varying degree. The most prominent was the statistically sig-
niﬁcant reduction in alpha2 and beta1a waves, correlated with
activation of the dopaminergic and glutamatergic transmitter
systems respectively. This feature is common to all synthetic and
herbal stimulants tested to date. The second strongest effects were
reduction in both the delta and the theta frequency ranges, cor-
related with changes in the cholinergic and norepinephrine sys-
tems respectively, a pattern seen in preparations prescribed for
neurodegenerative diseases. Theta wave reduction in common
with the delta, alpha2 and beta1 attenuation has been noted for
analgesic drugs. Attenuation of alpha1 waves emerged during the
highest dosage in all brain areas, a feature seen in all anti-
depressants. The dose dependent increase of gamma activity has
Fig. 6. Citicoline, rolipram and botanicals with similar effects to Zembrins (20–65 min): for other details see legend to Fig. 1. For historical reasons (content of database) only
6 frequency ranges are documented. Statistical signiﬁcance in comparison to control (vehicle) is documented by asterisks: *¼po0.05; **¼po0.01; ***¼po0.001.
Fig. 7. Discriminant analysis of electropharmacograms. Comparison of the elec-
tropharmacogram of orally given Zembrin2.5 (2.5 mg/kg); Zembrin5 (5.0 mg/kg)
and Zembrin10 (10.0 mg/kg). All preparations were administered orally. Patterns
of reference drugs providing similar spectral frequency changes according to the
results of the ﬁrst three discriminant functions are positioned in close neigh-
bourhood (see x, y and z coordinates). Close similarity with respect to relative
position and colour indicates similar spectral changes (Dimpfel, 2013). Data from
the ﬁrst recording period after administration (see Table 2). (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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and Schombert, 2015), however no conclusions could be made as
direct measurement of motion resulted in too high variability,
while gamma activity had already appeared simply with the ﬁrst
motion of the head.
Our database was interrogated by a special program designed
to detect similar actions on brain spectral power by comparing the
relationship of spectral frequency changes for each substance to
each other. (Please note that the patterns documented in Fig. 6 do
not contain gamma activity since gamma activity has only been
analyzed for in more recently studies). With respect to botanicals
or herbal preparations a special extract of Oenothera biennis con-
taining 50% polyphenols was recognized as the most similar herbal
preparation to the middle dosage of Zembrins. Extracts of Cimi-
cifuga racemosa and Ginkgo biloba showed a quite similar proﬁle of
changes to those for Zembrin. The electropharmacogram for
Ginkgo biloba extract was similar to that for Zembrins, with the
difference consisting of attenuation of alpha1 spectral power in
Ginkgo, an effect not apparent in the proﬁle for Zembrins at lower
doses. A close similarity to the action of Zembrins was also ob-
served for an extract of Rhodiola rosea. Rhodiola has been classiﬁed
as a so-called adaptogenic botanical, which helps one cope with
physical and emotional stress. The clinical efﬁcacy of a Rhodiola
rosea extract has been recently characterized using a combination
of fast dynamic EEG analysis (Neurocode-Tracking) in combination
with Eye-Tracking (now called “Enkephalovision”) (Dimpfel, 2014).
Finally, the synthetic preparations citicoline, originally devel-
oped to enhance cognitive function, and rolipram, originally de-
veloped as an antidepressant drug, showed a similar pattern of
frequency changes to that for Zembrins. Both rolipram and
Zembrins are PDE4 inhibitors, and were expected to have similar
electropharmacograms, rolipram prominently attenuated alpha1
spectral power, an activity correlated with serotonergic transmis-
sion, whereas Zembrins only attenuated alpha 1 spectral power
after administration of the highest dosage. A comparison of
Zembrins to reference extracts, citicoline and rolipram isdocumented in Fig. 6 including the dosages administered. One can
conclude from this comparison that the antidepressant activity of
Zembrins may only take place at higher dosages.
These results are conﬁrmed by discriminant analysis of the
data. The three dosages of Zembrins are projected together in
close vicinity and show the same colour, as documented in Fig. 7.
The comparison to other herbals as well as to citicoline and roli-
pram revealed that the nearest botanical preparation is an Oe-
nothera extract also showing the same colour as Zembrins. Other
herbal preparations, which are clearly difﬁcult to discriminate
from Zembrins are Cimicifuga racemosa extract and Gingko biloba
extract having a similar colour as seen for the lowest dosage of
Table 2
Listing of herbal and synthetic reference preparations used for the discriminant analysis. Doses and time of recording are given. Reference compounds are listed with dosage
given and time of recording after administration. Zembrins was given orally. A reference matrix of earlier tested drug actions is kept constant (preparations labelled as
“Substance Deﬁnition”) for classiﬁcation of unknown preparations (preparations labelled as “Substance Analysis”).
Substance Deﬁnition Dose [mg/kg] Appli-cation Time (min) Substance Analysis Dose [mg/kg] Appli-cation Time (min)
Kava–Kava 200 Orally 20–65 Avena 100 Orally 20–65
Guarana 25 Orally 20–65 Ginseng 100 Orally 20–65
Humulus 50 Orally 125–185 Passiﬂora 100 Orally 20–65
Valeriana 100 Orally 125–185 Oenothera 50 Orally 20–65
Ginkgo 100 Orally 20–65 Cimicifuga 75 Orally 20–65
Agnus-Castus 50 Orally 20–65 Camellia sin. 25 Orally 20–65
Rhodiola 100 Orally 20–65 Citicoline 48 Orally 20–65
Hypericum 250 Orally 20–65 Rolipram 0.1 Orally 20–65
Vehicle 0.0 Orally 20–65
Zembrin2.5 2.5 Orally 20–65
Zembrin5 5.0 Orally 20–65
Zembrin10 10.0 Orally 20–65
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are given in Table 2.
This statistical result indicates that Zembrins can be expected
to have similar CNS-related clinical properties in common with
Gingko biloba and Cimicifuga racemosa extract. With respect to the
similarity to Gingko biloba, positive cognitive and antidepressant
effects can be expected in terms of clinical use. A similar pattern of
electropharmacogram changes was found for Rhodiola rosea ex-
tract. According to discriminant analysis the projection of the ef-
fect of Rhodiola shows a rather similar colour in addition to its
spacial relationship to the middle dosage of Zembrins. Rhodiola
rosea extract is marketed in Germany and has been successfully
clinically tested for its activating and stimulant effects (Dimpfel,
2014). Despite having similar electropharmacograms, the fre-
quency pattern of citicoline in the discriminant analysis projects
citicoline some distance from Zembrins. Presumably, the lack of
effect of citicoline in the striatum may be the reason for the more
distant projection in the discriminant analysis.
The combined results from the electropharmacograms and
comparative discriminatory analyses suggest that Zembrins has
dose dependent activity, with potential applications as a cognitive
function enhancer, as an antidepressant, and as an analgesic.Acnowledgements
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